Christian Rommel (via Roche)
Bayer follows R&D deal spree by raiding Roche's cancer group for its new research chief
The day after Bayer signed off on a $4 billion deal designed to put the company among the leaders in gene therapy development, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
